Vaxcyte, Inc.
PCVXHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeVaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. At a $7.42B market cap, Vaxcyte, Inc. ranks as a mid-cap company within healthcare. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Market Cap
$7.42B
Beta
1.30
P/E (TTM)
—
P/E (Fwd)
-6.93
EPS (TTM)
$-6.89
EPS (Fwd)
$-7.42
ROE
-30.6%
ROA
-20.2%
Cash
$1.74B
Total Debt
$116.3M
Free CF
-$439.8M
52W Change
46.8%
Annual Financials
Cash vs Debt
Vaxcyte, Inc. holds $1.74B in cash against $116.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$439.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -30.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, PCVX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Vaxcyte, Inc.'s trajectory.